123 related articles for article (PubMed ID: 8632461)
1. Specificity of abnormal assembly in immunoglobulin light chain deposition disease and amyloidosis.
Helms LR; Wetzel R
J Mol Biol; 1996 Mar; 257(1):77-86. PubMed ID: 8632461
[TBL] [Abstract][Full Text] [Related]
2. Immunoglobulin kappa light chain and its amyloidogenic mutants: a molecular dynamics study.
Nowak M
Proteins; 2004 Apr; 55(1):11-21. PubMed ID: 14997536
[TBL] [Abstract][Full Text] [Related]
3. Both the environment and somatic mutations govern the aggregation pathway of pathogenic immunoglobulin light chain.
Davis DP; Gallo G; Vogen SM; Dul JL; Sciarretta KL; Kumar A; Raffen R; Stevens FJ; Argon Y
J Mol Biol; 2001 Nov; 313(5):1021-34. PubMed ID: 11700059
[TBL] [Abstract][Full Text] [Related]
4. Integrated expression of glomerular extracellular matrix proteins and beta 1 integrins in monoclonal light chain-related renal diseases.
Turbat-Herrera EA; Isaac J; Sanders PW; Truong LD; Herrera GA
Mod Pathol; 1997 May; 10(5):485-95. PubMed ID: 9160315
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of disease: monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease.
Buxbaum J
Hematol Oncol Clin North Am; 1992 Apr; 6(2):323-46. PubMed ID: 1582976
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary light chain deposition disease: report of five cases and review of the literature.
Bhargava P; Rushin JM; Rusnock EJ; Hefter LG; Franks TJ; Sabnis SG; Travis WD
Am J Surg Pathol; 2007 Feb; 31(2):267-76. PubMed ID: 17255772
[TBL] [Abstract][Full Text] [Related]
7. Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease.
Kaplan B; Ramirez-Alvarado M; Sikkink L; Golderman S; Dispenzieri A; Livneh A; Gallo G
Br J Haematol; 2009 Mar; 144(5):705-15. PubMed ID: 19076171
[TBL] [Abstract][Full Text] [Related]
8. Charge differences between in vivo deposits in immunoglobulin light chain amyloidosis and non-amyloid light chain deposition disease.
Kaplan B; Livneh A; Gallo G
Br J Haematol; 2007 Mar; 136(5):723-8. PubMed ID: 17223908
[TBL] [Abstract][Full Text] [Related]
9. Review: immunoglobulin light chain amyloidosis--the archetype of structural and pathogenic variability.
Bellotti V; Mangione P; Merlini G
J Struct Biol; 2000 Jun; 130(2-3):280-9. PubMed ID: 10940232
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical study of immunoglobulin light chain amyloidosis with antibodies to the immunoglobulin light chain variable region.
Hoshii Y; Kiyama M; Cui D; Kawano H; Ishihara T
Pathol Int; 2006 Jun; 56(6):324-30. PubMed ID: 16704496
[TBL] [Abstract][Full Text] [Related]
11. Binding of nascent collagen by amyloidogenic light chains and amyloid fibrillogenesis in monolayers of human fibrocytes.
Harris DL; King E; Ramsland PA; Edmundson AB
J Mol Recognit; 2000; 13(4):198-212. PubMed ID: 10931557
[TBL] [Abstract][Full Text] [Related]
12. Decreased amyloidogenicity caused by mutational modulation of surface properties of the immunoglobulin light chain BRE variable domain.
Kobayashi Y; Tsutsumi H; Abe T; Ikeda K; Tashiro Y; Unzai S; Kamikubo H; Kataoka M; Hiroaki H; Hamada D
Biochemistry; 2014 Aug; 53(31):5162-73. PubMed ID: 25062800
[TBL] [Abstract][Full Text] [Related]
13. Morphologic manifestations of combined light-chain deposition disease and light-chain cast nephropathy.
Gokden N; Cetin N; Colakoglu N; Kumar J; Abul-Ezz S; Barlogie B; Liapis H; Walker PD
Ultrastruct Pathol; 2007; 31(2):141-9. PubMed ID: 17613994
[TBL] [Abstract][Full Text] [Related]
14. [Immunoglobulin light chain amyloidosis: recent molecular, clinical and therapeutic approach].
Thierry A; Bridoux F; Goodman H; Belmouaz S; Abou Ayache R; Desport E; Jaccard A; Touchard G
Nephrologie; 2004; 25(4):111-8. PubMed ID: 15291138
[TBL] [Abstract][Full Text] [Related]
15. Morphologic heterogeneity of renal light-chain deposition disease.
Gokden N; Barlogie B; Liapis H
Ultrastruct Pathol; 2008; 32(1):17-24. PubMed ID: 18300034
[TBL] [Abstract][Full Text] [Related]
16. The V kappa III subgroup light chain proteins in AL amyloidosis & autoimmune diseases.
Alim MA; Hara Y; Kaji H; Shinoda T
Indian J Med Res; 2001 Jul; 114():30-5. PubMed ID: 11762204
[TBL] [Abstract][Full Text] [Related]
17. Fragments of the constant region of immunoglobulin light chains are constituents of AL-amyloid proteins.
Olsen KE; Sletten K; Westermark P
Biochem Biophys Res Commun; 1998 Oct; 251(2):642-7. PubMed ID: 9792827
[TBL] [Abstract][Full Text] [Related]
18. Interaction between glycosaminoglycans and immunoglobulin light chains.
Jiang X; Myatt E; Lykos P; Stevens FJ
Biochemistry; 1997 Oct; 36(43):13187-94. PubMed ID: 9341206
[TBL] [Abstract][Full Text] [Related]
19. A role for destabilizing amino acid replacements in light-chain amyloidosis.
Hurle MR; Helms LR; Li L; Chan W; Wetzel R
Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5446-50. PubMed ID: 8202506
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis, diagnosis and treatment of systemic amyloidosis.
Pepys MB
Philos Trans R Soc Lond B Biol Sci; 2001 Feb; 356(1406):203-10; discussion 210-1. PubMed ID: 11260801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
